Toll Like Receptor 4 (CD284 or TLR4) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research

Toll Like Receptor 4 (CD284 or TLR4) - Pipeline Review, H1 2016

Toll Like Receptor 4 (CD284 or TLR4) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research
Toll Like Receptor 4 (CD284 or TLR4) - Pipeline Review, H1 2016
Published Jun 30, 2016
116 pages — Published Jun 30, 2016
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Toll Like Receptor 4 (CD284 or TLR4) - Pipeline Review, H1 2016, provides in depth analysis on Toll Like Receptor 4 (CD284 or TLR4) targeted pipeline therapeutics.

The report provides comprehensive information on the Toll Like Receptor 4 (CD284 or TLR4), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Toll Like Receptor 4 (CD284 or TLR4) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Toll Like Receptor 4 (CD284 or TLR4)
- The report reviews Toll Like Receptor 4 (CD284 or TLR4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Toll Like Receptor 4 (CD284 or TLR4) targeted therapeutics and enlists all their major and minor projects
- The report assesses Toll Like Receptor 4 (CD284 or TLR4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Toll Like Receptor 4 (CD284 or TLR4) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Toll Like Receptor 4 (CD284 or TLR4)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focu

  
Source:
Document ID
GMDHC0189TDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents27
  List of Tables71
  List of Figures81
Introduction91
  Global Markets Direct Report Coverage91
Toll Like Receptor 4 (CD284 or TLR4) Overview101
Therapeutics Development115
  Toll Like Receptor 4 (CD284 or TLR4) Products under Development by Stage of Development111
  Toll Like Receptor 4 (CD284 or TLR4) Products under Development by Therapy Area121
  Toll Like Receptor 4 (CD284 or TLR4) Products under Development by Indication133
Toll Like Receptor 4 (CD284 or TLR4) Pipeline Products Glance162
  Late Stage Products161
  Early Stage Products171
Toll Like Receptor 4 (CD284 or TLR4) Products under Development by Companies185
Toll Like Receptor 4 (CD284 or TLR4) Products under Development by Universities/Institutes232
Toll Like Receptor 4 (CD284 or TLR4) Therapeutics Assessment257
  Assessment by Monotherapy/Combination Products251
  Assessment by Mechanism of Action262
  Assessment by Route of Administration282
  Assessment by Molecule Type302
Toll Like Receptor 4 (CD284 or TLR4) Companies Involved in Therapeutics Development3215
  Batu Biologics, Inc.321
  BioLineRx, Ltd.331
  Biomedica Management Corporation341
  Eisai Co., Ltd.351
  eTheRNA Immunotherapies NV361
  Formune S.L.371
  GlaxoSmithKline Plc381
  Harbor Therapeutics, Inc.391
  Immune Design Corp.401
  Immunovo BV411
  Kyorin Pharmaceutical Co., Ltd.421
  NovImmune SA431
  Reliance Life Sciences Pvt. Ltd.441
  TaiwanJ Pharmaceuticals Co., Ltd.451
  Vascular Biogenics Ltd.461
Toll Like Receptor 4 (CD284 or TLR4) Drug Profiles4753
  ApTLR-4FT Drug Profile471
  BL-1110 Drug Profile482
  C-34 Drug Profile501
  CRX-526 Drug Profile511
  DMT-210 Drug Profile521
  EDA-GP120 Drug Profile531
  EDA-HPVE7 Drug Profile541
  EDA-NS3 Drug Profile551
  EDA-TRP2 Drug Profile561
  eritoran tetrasodium Drug Profile572
  G-100 Drug Profile593
  Glyco-23 Drug Profile621
  GSK-1795091 Drug Profile631
  HE-3286 Drug Profile643
  hp-91 Drug Profile671
  ibudilast Drug Profile688
  JKB-117 Drug Profile761
  JKB-119 Drug Profile771
  JKB-121 Drug Profile781
  naltrexone hydrochloride Drug Profile792
  NI-0101 Drug Profile811
  Oligonucleotide to Activate CD40L, CD70 and TLR-4 for Oncology and Infectious Diseases Drug Profile821
  P-13 Drug Profile831
  P-16 Drug Profile841
  P-7 Drug Profile851
  P-MAPA Drug Profile862
  PEPA-10 Drug Profile881
  RSCL-0520 Drug Profile891
  Small Molecules to Antagonize TLR-4 for CNS Disorders Drug Profile901
  Small Molecules to Antagonize TLR2 and TLR4 for Immune inflammatory Diseases Drug Profile911
  Small Molecules to Antagonize TLR4 for Acute Lung Injury and Bacterial Sepsis Drug Profile921
  Small Molecules to Antagonize Toll-Like Receptor 4 for Oncology and Autoimmune Disorders Drug Profile931
  Synthetic Peptide to Antagonize TLR-4 for Oncology, Immunology and Infectious Disease Drug Profile941
  VB-201 Drug Profile953
  VB-3323 Drug Profile981
  VB-703 Drug Profile991
Toll Like Receptor 4 (CD284 or TLR4) Dormant Projects1004
Toll Like Receptor 4 (CD284 or TLR4) Discontinued Products1041
Toll Like Receptor 4 (CD284 or TLR4) Featured News &Press Releases10510
  Jun 08, 2016: Immune Design Announces Updated Results For Its Immuno-oncology Product Candidate G100 At ASCO1051
  May 25, 2016: MediciNova Announces Additional Results from the Completed Trial of MN-166 (ibudilast) in Alcohol Dependence to be Presented at the 39th Annual Scientific Meeting of the Research Society on Alcoholism in New Orleans, Louisiana1051
  May 16, 2016: Dermata Therapeutics Announces Initiation of Phase 1 Pharmacokinetic Study1061
  Apr 21, 2016: Immune Design Announces Presentations on G-100 at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting1061
  Apr 20, 2016: MediciNova Announces Interim Data from Clinical Trial of MN-166 (ibudilast) in ALS Presented at the American Academy of Neurology (AAN) 68th Annual Meeting in Vancouver, Canada1071
  Apr 20, 2016: Immune Design Presents New Preclinical Data on Advances of Two Separate Intratumoral Approaches at the American Association for Cancer Research (AACR) Annual Meeting 20161081
  Mar 30, 2016: MediciNova Announces Publication of Positive Findings from Completed Phase 1b Clinical Trial of MN-166 (ibudilast) in Methamphetamine Dependence1091
  Mar 22, 2016: FDA Grants Fast Track Designation for MediciNovas MN-166 (ibudilast) for Progressive Multiple Sclerosis1101
  Mar 07, 2016: MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Amyotrophic Lateral Sclerosis1111
  Mar 06, 2016: MediciNova Announces Positive Findings From a Completed Phase 2 Trial of MN-166 (ibudilast) in Opioid Dependence at the Behavior, Biology and Chemistry: Translational Research in Addiction Meeting in San Antonio, Texas1111
  Feb 22, 2016: MediciNova Announces MN-166 (ibudilast) ALS Abstract Accepted for Dual Presentation at the American Academy of Neurology 68th Annual Meeting in Vancouver, Canada1121
  Feb 11, 2016: MediciNova Announces Presentation Regarding MN-166 (ibudilast) and Methamphetamine Dependence at the Behavior, Biology and Chemistry Annual Meeting and Symposium in San Antonio, Texas1131
  Feb 09, 2016: Immune Design Announces Data From Phase 1 Clinical Trial of G1001131
  Feb 07, 2016: MediciNova Announces Presentation of Data From the Completed Phase 2 Trial of MN-166 (ibudilast) in Opioid Dependence at the Behavior, Biology and Chemistry Annual Meeting and Symposium in San Antonio, Texas1131
  Jan 18, 2016: FDA Grants Rare Pediatric Disease Designation to MediciNova s MN-166 (ibudilast) for the Treatment of Krabbe Disease1141
Appendix1152
  Methodology1151
  Coverage1151
  Secondary Research1151
  Primary Research1151
  Expert Panel Validation1151
  Contact Us1151
  Disclaimer1161

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Toll Like Receptor 4 (CD284 or TLR4) - Pipeline Review, H1 2016" Jun 30, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Toll-Like-Receptor-4-CD284-or-TLR4-Pipeline-Review-H1-2016-2088-16087>
  
APA:
Global Markets Direct - Market Research. (2016). Toll Like Receptor 4 (CD284 or TLR4) - Pipeline Review, H1 2016 Jun 30, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Toll-Like-Receptor-4-CD284-or-TLR4-Pipeline-Review-H1-2016-2088-16087>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.